Choksi Laboratories (BOM:526546) Cyclically Adjusted Revenue per Share: ₹61.94 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BOM:526546 Choksi Laboratories Ltd BOM:526546
51 GF Score
Price ₹165.25
GF Value ₹109.07
Valuation Significantly Overvalued
! 4 Warning Signs
View Full Analysis

What is Choksi Laboratories Cyclically Adjusted Revenue per Share?

Choksi Laboratories BOM:526546 -0.69% 51 Cyclically Adjusted Revenue per Share is ₹61.94 as of Jun. 2026. GuruFocus rates BOM:526546 with a GF Score™ of 51/100 and a GF Value™ of ₹109.07 (Significantly Overvalued). The stock has 4 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Choksi Laboratories's adjusted revenue per share for the three months ended in Jun. 2026 was ₹17.399. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is ₹61.94 for the trailing ten years ended in Jun. 2026.

During the past 12 months, Choksi Laboratories's average Cyclically Adjusted Revenue Growth Rate was 7.30% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 5.40% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was 5.40% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Choksi Laboratories was 5.40% per year. The lowest was 5.30% per year. And the median was 5.40% per year.

As of today (2026-09-04), Choksi Laboratories's current stock price is ₹165.25. Choksi Laboratories's Cyclically Adjusted Revenue per Share for the quarter that ended in Jun. 2026 was ₹61.94. Choksi Laboratories's Cyclically Adjusted PS Ratio of today is 2.67.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Choksi Laboratories was 3.81. The lowest was 0.17. And the median was 1.06.


Choksi Laboratories  (BOM:526546) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Choksi Laboratories's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=165.25/61.94
=2.67

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Choksi Laboratories was 3.81. The lowest was 0.17. And the median was 1.06.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Choksi Laboratories Cyclically Adjusted Revenue per Share Related Terms


Choksi Laboratories Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Choksi Laboratories's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Choksi Laboratories Cyclically Adjusted Revenue per Share Chart

Choksi Laboratories Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 48.17 51.42 54.04 56.44 60.27

Choksi Laboratories Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 57.72 59.05 59.76 60.27 61.94

BOM:526546 vs TMO, DHR, NTRA: Cyclically Adjusted Revenue per Share Comparison

For the Diagnostics & Research subindustry, Choksi Laboratories's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Choksi Laboratories Cyclically Adjusted PS Ratio vs Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Choksi Laboratories's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Choksi Laboratories's Cyclically Adjusted PS Ratio falls into.


BOM:526546
51GF Score
Choksi Laboratories Ltd BOM:526546
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Choksi Laboratories Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Choksi Laboratories's adjusted Revenue per Share data for the three months ended in Jun. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=17.399/167.3573*167.3573
=17.399

Current CPI (Jun. 2026) = 167.3573.

Choksi Laboratories Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201609 10.775 105.961 17.018
201612 9.331 105.196 14.845
201703 12.649 105.196 20.123
201706 9.259 107.109 14.467
201709 10.418 109.021 15.993
201712 12.631 109.404 19.322
201803 18.250 109.786 27.820
201806 11.721 111.317 17.622
201809 12.117 115.142 17.612
201812 11.678 115.142 16.974
201903 13.077 118.202 18.515
201906 11.600 120.880 16.060
201909 10.057 123.175 13.664
201912 9.684 126.235 12.839
202003 9.021 124.705 12.106
202006 6.923 127.000 9.123
202009 10.589 130.118 13.620
202012 8.864 130.889 11.334
202103 10.586 131.771 13.445
202106 7.631 134.084 9.525
202109 10.295 135.847 12.683
202112 10.307 138.161 12.485
202203 14.518 138.822 17.502
202206 11.848 142.347 13.930
202209 12.122 144.661 14.024
202212 11.270 145.763 12.940
202303 14.092 146.865 16.058
202306 12.581 150.280 14.011
202309 11.692 151.492 12.916
202312 12.685 152.924 13.882
202403 16.222 153.035 17.740
202406 15.311 155.789 16.448
202409 13.494 157.882 14.304
202412 14.723 158.323 15.563
202503 16.332 157.552 17.348
202506 16.060 159.755 16.824
202509 16.072 162.289 16.574
202512 15.693 163.281 16.085
202603 18.357 164.272 18.702
202606 17.399 167.357 17.399

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of ₹61.94 mean?
Choksi Laboratories (BOM:526546) has a Cyclically Adjusted Revenue per Share of ₹61.94 as of Jun. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Choksi Laboratories and its competitors.
Is Choksi Laboratories' Cyclically Adjusted Revenue per Share too high?
Choksi Laboratories' current Cyclically Adjusted Revenue per Share is ₹61.94. Overall, Choksi Laboratories has a GF Score™ of 51/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Choksi Laboratories' Cyclically Adjusted Revenue per Share compare to TMO and DHR?
Choksi Laboratories' Cyclically Adjusted Revenue per Share of ₹61.94 can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Medical Diagnostics & Research company?
A good Cyclically Adjusted Revenue per Share depends on the Medical Diagnostics & Research industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Choksi Laboratories and its competitors. Choksi Laboratories's current Cyclically Adjusted Revenue per Share is ₹61.94. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Choksi Laboratories stock overvalued right now?
Based on GuruFocus' analysis, Choksi Laboratories (BOM:526546) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹109.07, compared to a current price of ₹165.25 — trading 51.5% above its estimated fair value. The current Cyclically Adjusted Revenue per Share is ₹61.94. Choksi Laboratories' overall GF Score™ is 51/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Choksi Laboratories (BOM:526546), the current Cyclically Adjusted Revenue per Share is ₹61.94 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Choksi Laboratories (BOM:526546) Overvalued in 2026?

Based on GuruFocus' analysis, Choksi Laboratories stock appears to be overvalued. The current stock price of ₹165.25 is trading 51.5% above its estimated GF Value™ of ₹109.07. GuruFocus considers Choksi Laboratories to be Significantly Overvalued.

Key valuation signals for BOM:526546:

  • Cyclically Adjusted Revenue per Share: ₹61.94
  • GF Value™: ₹109.07 vs. price of ₹165.25 (51.5% above fair value)
  • GF Score™: 51/100 with 4 warning signs

No single metric tells the full story. See the BOM:526546 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Choksi Laboratories Business Description

Address Survey no. 9/1, Near Tulsiyana Industrial Park, Gram Kumerdi, Indore, MP, IND, 452010
Choksi Laboratories Ltd is an analysis and research company. The company provides contract testing and analytical services. The Company analyzes for its clients as a regulatory requirement pharmaceuticals, food and agricultural products, construction materials, chemicals, Calibration and environment Monitoring services.
51GF Score

Get the complete analysis for BOM:526546

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹165.25
Price
₹109.07
GF Value